TWI274585B - Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus - Google Patents

Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus Download PDF

Info

Publication number
TWI274585B
TWI274585B TW092114876A TW92114876A TWI274585B TW I274585 B TWI274585 B TW I274585B TW 092114876 A TW092114876 A TW 092114876A TW 92114876 A TW92114876 A TW 92114876A TW I274585 B TWI274585 B TW I274585B
Authority
TW
Taiwan
Prior art keywords
virus
flaviviridae
treating
pharmaceutical composition
infection
Prior art date
Application number
TW092114876A
Other languages
English (en)
Chinese (zh)
Other versions
TW200307558A (en
Inventor
Tsu-An Hsu
Yuan-Chin Tsai
Der-Ren Hwang
Original Assignee
Nat Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Health Research Institutes filed Critical Nat Health Research Institutes
Publication of TW200307558A publication Critical patent/TW200307558A/zh
Application granted granted Critical
Publication of TWI274585B publication Critical patent/TWI274585B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Packages (AREA)
TW092114876A 2002-06-03 2003-06-02 Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus TWI274585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38503102P 2002-06-03 2002-06-03

Publications (2)

Publication Number Publication Date
TW200307558A TW200307558A (en) 2003-12-16
TWI274585B true TWI274585B (en) 2007-03-01

Family

ID=29550193

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092114876A TWI274585B (en) 2002-06-03 2003-06-02 Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus

Country Status (7)

Country Link
EP (1) EP1369120B1 (https=)
JP (1) JP2004131466A (https=)
KR (1) KR20030094097A (https=)
CN (1) CN1251687C (https=)
AT (1) ATE353658T1 (https=)
DE (1) DE60311702T2 (https=)
TW (1) TWI274585B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090058423A (ko) * 2007-12-04 2009-06-09 심형섭 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
TWI605822B (zh) * 2015-04-09 2017-11-21 高雄醫學大學 酪梨萃取物、ａｖｏｃａｄｅｎｏｌ Ｂ及（２Ｒ，４Ｒ）－１，２，４－三羥基十七碳－１６－炔的用途，以及包含酪梨萃取物之保健食品
EP3815699A1 (en) * 2019-10-28 2021-05-05 Technische Universität München New means and methods for therapy and diagnosis of adenoviral infection
IL295648A (en) * 2020-02-16 2022-10-01 Komipharm Int Australia Pty Ltd treatment method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214419D0 (en) * 1992-07-07 1992-08-19 Concannon Peter Biocidal agents
JPH0769903A (ja) * 1993-07-01 1995-03-14 Hatsuchiyou:Kk 抗ヒト免疫不全ウイルス剤およびエイズ治療薬
WO1995011033A1 (en) * 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
JP4420997B2 (ja) * 1999-02-08 2010-02-24 利博 山瀬 抗ウィルス剤
AU4463300A (en) * 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
JP2001233719A (ja) * 1999-12-13 2001-08-28 Natl Inst Of Advanced Industrial Science & Technology Meti 殺菌材および殺菌方法
WO2001049302A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Compositions and methods for facilitating skin growth and managing skin conditions
US7744867B2 (en) * 2001-05-31 2010-06-29 The Cleveland Clinic Foundation PTPase inhibitors and method of using same

Also Published As

Publication number Publication date
JP2004131466A (ja) 2004-04-30
DE60311702D1 (de) 2007-03-29
DE60311702T2 (de) 2007-10-31
EP1369120A1 (en) 2003-12-10
CN1483413A (zh) 2004-03-24
CN1251687C (zh) 2006-04-19
TW200307558A (en) 2003-12-16
ATE353658T1 (de) 2007-03-15
KR20030094097A (ko) 2003-12-11
EP1369120B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
JP2024003097A (ja) コロナウイルス感染の治療におけるファビピラビルの使用
CA2853495A1 (en) Methods and compositions for treating hepatitis c virus
Meites et al. Fatal Clostridium sordellii infections after medical abortions
WO2021147273A1 (zh) 硝唑尼特及其活性形式替唑尼特在治疗SARS-CoV-2感染中的应用
Lee Page et al. Possible interaction between intravenous azithromycin and oral cyclosporine
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
TWI274585B (en) Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
EP3785718A1 (en) Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
Hiramatsu et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
ES2684396T3 (es) Heterociclil carboxamidas para tratar enfermedades víricas
US7482149B2 (en) Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
WO2008004653A1 (en) Prophylactic or therapeutic agent for viral disease
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
Fernández-Montero et al. Treatment of hepatitis C in HIV patients in the new era of direct-acting antivirals
Bzowej et al. A RANDOMIZED CONTROLLED TRIAL OF PROPHYLACTICALLY ADMINISTERED PEGINTERFERON ALFA-2A PLUS RIBAVIRIN VS NO PROPHYLAXIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION (OLT) FOR HEPATITIS C: A REPORT OF INITIAL SAFETY AND TOLERABILITY: 2
WO2025183089A1 (ja) 潜伏感染しているｈｉｖを再活性化するための組成物
Ketabi et al. Comparison of PEG interferon loaded and non-loaded iron oxide nanoparticles on hepatitis C virus replication in cell culture system
KR20250054355A (ko) 경구용 c형간염 바이러스 치료제
Xu et al. Initiation of Long-Acting Antiretroviral Combinations Achieve Sustained Virologic Remission in Early-Life SIV Infection
Huynh et al. Clinical Pharmacist’s Role in Successful Retreatment of Glecaprevir/Pibrentasvir Virologic Failure with Prolonged Treatment Duration and Low Dose Ribavirin in Hepatitis C Patient with End-Stage Renal Disease: A Case Report
Chevaliez et al. 744 IN VIVO AND IN VITRO RESISTANCE TO SILIBININ, A COMPONENT OF SILYMARIN AND POTENT INHIBITOR OF HCV REPLICATION
TW202207968A (zh) 棘白菌素類化合物於治療黃病毒感染症的用途
Bottecchia et al. 743 NATURALLY OCCURRING DRUG RESISTANCE MUTATIONS IN THE HEPATITIS C VIRUS NS3 PROTEASE IN HIV/HCV COINFECTED PATIENTS TREATED WITH HIV PROTEASE INHIBITORS
Bader et al. 742 ROSUVASTATIN COMPARED TO FLUVASTATIN, SIMVASTATIN, AND RIBAVIRIN FOR ANTI-HCV ACTIVITY IN VITRO
Lawitz et al. 997 Triple therapy compared to standard pegylated interferon alfa 2B+ weight based ribavirin for treatment naive chronic hepatitis C [tri-star trial]: final results

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees